| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 20 | 2018 | 778 | 2.200 |
Why?
|
| Genetic Therapy | 13 | 2012 | 291 | 2.030 |
Why?
|
| Galactosylgalactosylglucosylceramidase | 9 | 2008 | 39 | 1.510 |
Why?
|
| Sphingolipids | 12 | 2019 | 337 | 1.300 |
Why?
|
| Ceramides | 16 | 2019 | 578 | 1.190 |
Why?
|
| Antineoplastic Agents | 13 | 2018 | 1070 | 1.190 |
Why?
|
| Acid Ceramidase | 7 | 2020 | 85 | 1.110 |
Why?
|
| Apoptosis | 17 | 2020 | 1641 | 1.070 |
Why?
|
| Adenoviridae | 11 | 2006 | 295 | 1.040 |
Why?
|
| Enzyme Inhibitors | 8 | 2017 | 659 | 1.040 |
Why?
|
| Fas Ligand Protein | 11 | 2012 | 64 | 1.010 |
Why?
|
| Membrane Glycoproteins | 8 | 2005 | 370 | 0.710 |
Why?
|
| Head and Neck Neoplasms | 5 | 2010 | 561 | 0.650 |
Why?
|
| Genetic Vectors | 9 | 2008 | 312 | 0.610 |
Why?
|
| Cell Line, Tumor | 20 | 2019 | 1851 | 0.570 |
Why?
|
| Tumor Cells, Cultured | 6 | 2020 | 852 | 0.560 |
Why?
|
| Capsid Proteins | 2 | 2006 | 27 | 0.550 |
Why?
|
| Neoplasms | 6 | 2013 | 1667 | 0.480 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2020 | 756 | 0.480 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2006 | 626 | 0.420 |
Why?
|
| Cadherins | 1 | 2012 | 93 | 0.400 |
Why?
|
| Antigens, CD | 1 | 2012 | 230 | 0.390 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2012 | 135 | 0.380 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 235 | 0.370 |
Why?
|
| Desipramine | 2 | 2006 | 47 | 0.350 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2010 | 629 | 0.340 |
Why?
|
| Animals | 28 | 2020 | 20881 | 0.340 |
Why?
|
| Up-Regulation | 7 | 2012 | 682 | 0.330 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2006 | 45 | 0.280 |
Why?
|
| Humans | 45 | 2020 | 68618 | 0.280 |
Why?
|
| Cysteine Endopeptidases | 1 | 2006 | 39 | 0.270 |
Why?
|
| Propanolamines | 4 | 2013 | 70 | 0.270 |
Why?
|
| Bacteriophages | 2 | 2003 | 24 | 0.270 |
Why?
|
| Mice, Nude | 8 | 2013 | 294 | 0.270 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2010 | 174 | 0.250 |
Why?
|
| Mice | 18 | 2020 | 8474 | 0.250 |
Why?
|
| Amides | 3 | 2013 | 86 | 0.250 |
Why?
|
| Bacteriophage P1 | 3 | 2003 | 11 | 0.240 |
Why?
|
| Escherichia coli | 3 | 2003 | 368 | 0.230 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2005 | 138 | 0.230 |
Why?
|
| Male | 23 | 2018 | 37321 | 0.230 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2013 | 304 | 0.220 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2020 | 99 | 0.220 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2007 | 411 | 0.220 |
Why?
|
| Down-Regulation | 3 | 2012 | 447 | 0.220 |
Why?
|
| Bacterial Toxins | 1 | 2003 | 50 | 0.220 |
Why?
|
| Escherichia coli Proteins | 1 | 2003 | 65 | 0.210 |
Why?
|
| Caspases | 5 | 2007 | 194 | 0.210 |
Why?
|
| Bacteriophage M13 | 1 | 2002 | 12 | 0.210 |
Why?
|
| Virus Replication | 1 | 2002 | 104 | 0.200 |
Why?
|
| Bacterial Infections | 1 | 2003 | 163 | 0.190 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2013 | 35 | 0.190 |
Why?
|
| Biomarkers, Tumor | 3 | 2020 | 508 | 0.190 |
Why?
|
| RNA, Small Interfering | 4 | 2019 | 434 | 0.180 |
Why?
|
| Doxorubicin | 1 | 2002 | 231 | 0.180 |
Why?
|
| Blotting, Western | 5 | 2019 | 954 | 0.180 |
Why?
|
| Arthritis, Experimental | 1 | 2020 | 38 | 0.180 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2020 | 77 | 0.180 |
Why?
|
| Chemokine CXCL13 | 2 | 2010 | 8 | 0.180 |
Why?
|
| Antigen Presentation | 1 | 2020 | 76 | 0.180 |
Why?
|
| Tamoxifen | 1 | 2020 | 62 | 0.170 |
Why?
|
| Myristates | 3 | 2008 | 21 | 0.170 |
Why?
|
| Lipid Metabolism | 2 | 2018 | 186 | 0.160 |
Why?
|
| Autoimmune Diseases | 1 | 2020 | 186 | 0.160 |
Why?
|
| Membrane Proteins | 1 | 2003 | 617 | 0.160 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2020 | 282 | 0.160 |
Why?
|
| Sphingomyelin Phosphodiesterase | 4 | 2010 | 183 | 0.160 |
Why?
|
| Amidohydrolases | 3 | 2007 | 60 | 0.150 |
Why?
|
| Myristic Acid | 1 | 2017 | 6 | 0.150 |
Why?
|
| Phosphotransferases | 1 | 2017 | 16 | 0.150 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2017 | 26 | 0.150 |
Why?
|
| Acyltransferases | 1 | 2017 | 40 | 0.150 |
Why?
|
| Mouth Neoplasms | 2 | 2010 | 206 | 0.150 |
Why?
|
| Genes, Reporter | 3 | 2006 | 191 | 0.150 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2010 | 710 | 0.140 |
Why?
|
| Farber Lipogranulomatosis | 1 | 2016 | 5 | 0.140 |
Why?
|
| Promoter Regions, Genetic | 4 | 2013 | 615 | 0.130 |
Why?
|
| Lysosomes | 2 | 2007 | 136 | 0.130 |
Why?
|
| Cell Survival | 4 | 2010 | 901 | 0.130 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2015 | 306 | 0.130 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2017 | 284 | 0.130 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2013 | 332 | 0.130 |
Why?
|
| Bystander Effect | 2 | 2006 | 10 | 0.120 |
Why?
|
| Disease Progression | 3 | 2017 | 1038 | 0.120 |
Why?
|
| Transgenes | 2 | 2006 | 92 | 0.120 |
Why?
|
| Sphingosine | 6 | 2015 | 315 | 0.120 |
Why?
|
| fas Receptor | 2 | 2005 | 54 | 0.120 |
Why?
|
| Ligands | 3 | 2005 | 317 | 0.120 |
Why?
|
| Radiation Tolerance | 1 | 2013 | 30 | 0.110 |
Why?
|
| Apoptosis Regulatory Proteins | 3 | 2003 | 100 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 2 | 2012 | 369 | 0.110 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 3 | 2003 | 65 | 0.110 |
Why?
|
| Cytoplasm | 1 | 2013 | 155 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 2 | 2015 | 332 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2013 | 446 | 0.110 |
Why?
|
| RNA Interference | 3 | 2010 | 266 | 0.110 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2013 | 108 | 0.110 |
Why?
|
| Gene Expression Regulation, Bacterial | 2 | 2003 | 50 | 0.110 |
Why?
|
| Catenins | 1 | 2012 | 8 | 0.100 |
Why?
|
| Lysophospholipids | 5 | 2015 | 209 | 0.100 |
Why?
|
| RANK Ligand | 2 | 2010 | 73 | 0.100 |
Why?
|
| Cell Nucleus | 1 | 2013 | 305 | 0.100 |
Why?
|
| Cytokines | 1 | 2016 | 866 | 0.100 |
Why?
|
| Mortierella | 1 | 2011 | 1 | 0.100 |
Why?
|
| Cytoskeleton | 1 | 2012 | 84 | 0.100 |
Why?
|
| Genome, Fungal | 1 | 2011 | 6 | 0.100 |
Why?
|
| Cell Movement | 2 | 2012 | 630 | 0.100 |
Why?
|
| Breast Neoplasms | 2 | 2020 | 1536 | 0.100 |
Why?
|
| Ceramidases | 3 | 2007 | 47 | 0.100 |
Why?
|
| Cell Death | 1 | 2012 | 329 | 0.100 |
Why?
|
| Laryngeal Neoplasms | 1 | 2012 | 47 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 331 | 0.100 |
Why?
|
| Adenocarcinoma | 1 | 2013 | 475 | 0.090 |
Why?
|
| Osteolysis | 1 | 2010 | 15 | 0.090 |
Why?
|
| Lipids | 1 | 2011 | 298 | 0.090 |
Why?
|
| Interleukins | 1 | 2010 | 79 | 0.090 |
Why?
|
| Viral Proteins | 2 | 2007 | 150 | 0.080 |
Why?
|
| Prostate | 1 | 2009 | 116 | 0.080 |
Why?
|
| Enzyme Activation | 2 | 2008 | 791 | 0.080 |
Why?
|
| Cell Line | 5 | 2020 | 1752 | 0.080 |
Why?
|
| Gene Expression | 2 | 2013 | 770 | 0.080 |
Why?
|
| Cell Division | 2 | 2020 | 541 | 0.080 |
Why?
|
| Carcinoma | 1 | 2010 | 215 | 0.080 |
Why?
|
| Recombinant Proteins | 2 | 2010 | 742 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2007 | 231 | 0.080 |
Why?
|
| Chicken anemia virus | 1 | 2008 | 5 | 0.080 |
Why?
|
| Adenovirus E1A Proteins | 1 | 2007 | 6 | 0.080 |
Why?
|
| Flow Cytometry | 3 | 2019 | 489 | 0.070 |
Why?
|
| Mitochondria | 1 | 2012 | 643 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2006 | 376 | 0.070 |
Why?
|
| Indicators and Reagents | 1 | 2007 | 63 | 0.070 |
Why?
|
| Subcellular Fractions | 1 | 2007 | 92 | 0.070 |
Why?
|
| Antibodies | 2 | 2005 | 241 | 0.070 |
Why?
|
| Mitochondrial Membranes | 1 | 2007 | 45 | 0.070 |
Why?
|
| Membrane Potentials | 1 | 2007 | 200 | 0.070 |
Why?
|
| Signal Transduction | 4 | 2013 | 2689 | 0.070 |
Why?
|
| Hyaluronan Receptors | 1 | 2008 | 142 | 0.070 |
Why?
|
| Phosphoserine | 1 | 2006 | 14 | 0.070 |
Why?
|
| Endosomes | 1 | 2006 | 45 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 236 | 0.070 |
Why?
|
| Hyaluronic Acid | 1 | 2008 | 206 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2008 | 1753 | 0.070 |
Why?
|
| Hydrolysis | 1 | 2006 | 144 | 0.070 |
Why?
|
| Microscopy, Confocal | 1 | 2007 | 337 | 0.070 |
Why?
|
| Nuclear Proteins | 1 | 2007 | 271 | 0.070 |
Why?
|
| Cell Cycle | 2 | 2020 | 312 | 0.070 |
Why?
|
| Protein Transport | 1 | 2006 | 280 | 0.060 |
Why?
|
| Dinoprostone | 1 | 2006 | 110 | 0.060 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2007 | 618 | 0.060 |
Why?
|
| Plasmids | 2 | 2003 | 258 | 0.060 |
Why?
|
| Tumor Necrosis Factors | 1 | 2005 | 4 | 0.060 |
Why?
|
| Recoverin | 1 | 2005 | 3 | 0.060 |
Why?
|
| Viral Vaccines | 1 | 2005 | 17 | 0.060 |
Why?
|
| Cytosine Deaminase | 1 | 2005 | 8 | 0.060 |
Why?
|
| Thymidine Kinase | 1 | 2005 | 18 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2007 | 215 | 0.060 |
Why?
|
| Genes, p53 | 1 | 2005 | 41 | 0.060 |
Why?
|
| Antigens, Surface | 1 | 2005 | 71 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 2 | 2005 | 511 | 0.060 |
Why?
|
| Cell Membrane | 1 | 2006 | 525 | 0.060 |
Why?
|
| DNA, Bacterial | 2 | 2002 | 150 | 0.060 |
Why?
|
| Calcium-Binding Proteins | 1 | 2005 | 114 | 0.060 |
Why?
|
| bcl-2-Associated X Protein | 2 | 2002 | 111 | 0.060 |
Why?
|
| Mucins | 1 | 2004 | 22 | 0.060 |
Why?
|
| Female | 7 | 2020 | 38074 | 0.060 |
Why?
|
| Lipoproteins | 1 | 2005 | 161 | 0.060 |
Why?
|
| Eye Proteins | 1 | 2005 | 160 | 0.060 |
Why?
|
| Gram-Positive Cocci | 1 | 2003 | 5 | 0.060 |
Why?
|
| Mice, Inbred ICR | 1 | 2003 | 44 | 0.060 |
Why?
|
| Dexamethasone | 1 | 2004 | 150 | 0.050 |
Why?
|
| Jurkat Cells | 1 | 2003 | 59 | 0.050 |
Why?
|
| Caspase Inhibitors | 1 | 2003 | 36 | 0.050 |
Why?
|
| Genetic Engineering | 1 | 2003 | 41 | 0.050 |
Why?
|
| Complement System Proteins | 1 | 2004 | 135 | 0.050 |
Why?
|
| Hot Temperature | 1 | 2003 | 152 | 0.050 |
Why?
|
| Mathematical Computing | 1 | 2002 | 12 | 0.050 |
Why?
|
| Spleen | 1 | 2003 | 301 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2003 | 228 | 0.050 |
Why?
|
| Glioma | 1 | 2003 | 140 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2003 | 216 | 0.050 |
Why?
|
| Structure-Activity Relationship | 2 | 2017 | 420 | 0.050 |
Why?
|
| Transformation, Genetic | 1 | 2002 | 14 | 0.050 |
Why?
|
| Carrier Proteins | 2 | 2003 | 597 | 0.050 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2017 | 194 | 0.050 |
Why?
|
| Cytochrome c Group | 1 | 2002 | 22 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2004 | 222 | 0.050 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 1 | 2002 | 22 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 1 | 2003 | 261 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 848 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2002 | 39 | 0.050 |
Why?
|
| Androgens | 1 | 2002 | 41 | 0.050 |
Why?
|
| Cell Count | 1 | 2002 | 248 | 0.050 |
Why?
|
| Gram-Negative Bacteria | 1 | 2002 | 55 | 0.050 |
Why?
|
| DNA, Viral | 1 | 2002 | 114 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-jun | 2 | 2013 | 71 | 0.050 |
Why?
|
| Transduction, Genetic | 3 | 2010 | 81 | 0.050 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2002 | 133 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2017 | 1200 | 0.050 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 2 | 2015 | 201 | 0.050 |
Why?
|
| HLA-DR4 Antigen | 1 | 2020 | 11 | 0.050 |
Why?
|
| Base Sequence | 4 | 2003 | 1015 | 0.050 |
Why?
|
| Gene Expression Regulation | 1 | 2006 | 1293 | 0.050 |
Why?
|
| Cell Proliferation | 2 | 2020 | 1174 | 0.050 |
Why?
|
| Cathepsins | 1 | 2020 | 37 | 0.050 |
Why?
|
| Mice, Inbred DBA | 1 | 2020 | 120 | 0.050 |
Why?
|
| Antigen-Presenting Cells | 1 | 2020 | 50 | 0.050 |
Why?
|
| Transcriptional Activation | 2 | 2013 | 226 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2003 | 371 | 0.040 |
Why?
|
| A549 Cells | 1 | 2019 | 50 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2020 | 226 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2020 | 329 | 0.040 |
Why?
|
| Cisplatin | 1 | 2019 | 192 | 0.040 |
Why?
|
| Models, Biological | 1 | 2002 | 981 | 0.040 |
Why?
|
| Combinatorial Chemistry Techniques | 2 | 2007 | 25 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2017 | 137 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2007 | 111 | 0.040 |
Why?
|
| Stereoisomerism | 2 | 2007 | 169 | 0.040 |
Why?
|
| Survival Rate | 1 | 2020 | 1056 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2017 | 238 | 0.040 |
Why?
|
| Hexosaminidases | 1 | 2016 | 7 | 0.040 |
Why?
|
| Mutation, Missense | 1 | 2017 | 112 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2017 | 2673 | 0.040 |
Why?
|
| Macrophages | 1 | 2020 | 647 | 0.030 |
Why?
|
| Arthritis, Juvenile | 1 | 2016 | 70 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2017 | 326 | 0.030 |
Why?
|
| Molecular Structure | 2 | 2007 | 397 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 2016 | 149 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2015 | 2550 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2015 | 122 | 0.030 |
Why?
|
| Adamantane | 1 | 2015 | 40 | 0.030 |
Why?
|
| Protein Isoforms | 2 | 2007 | 246 | 0.030 |
Why?
|
| Prognosis | 1 | 2020 | 2093 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 2 | 2007 | 532 | 0.030 |
Why?
|
| Gene Transfer Techniques | 2 | 2008 | 173 | 0.030 |
Why?
|
| Kidney Neoplasms | 1 | 2015 | 206 | 0.030 |
Why?
|
| Karyopherins | 1 | 2013 | 11 | 0.030 |
Why?
|
| Pyridines | 1 | 2015 | 261 | 0.030 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2013 | 55 | 0.030 |
Why?
|
| Taxoids | 1 | 2013 | 41 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 1 | 2013 | 89 | 0.030 |
Why?
|
| Transcription Factor AP-1 | 1 | 2013 | 61 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 2013 | 119 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2013 | 160 | 0.030 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2013 | 66 | 0.030 |
Why?
|
| Transfection | 2 | 2008 | 782 | 0.030 |
Why?
|
| Lac Operon | 2 | 2003 | 54 | 0.030 |
Why?
|
| Carbocyanines | 1 | 2012 | 13 | 0.030 |
Why?
|
| Luminescent Proteins | 2 | 2003 | 57 | 0.030 |
Why?
|
| Cytochromes c | 1 | 2012 | 75 | 0.030 |
Why?
|
| Spectrum Analysis | 1 | 2012 | 81 | 0.030 |
Why?
|
| Coloring Agents | 1 | 2012 | 66 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2013 | 223 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2012 | 77 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2012 | 83 | 0.030 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2012 | 93 | 0.030 |
Why?
|
| Green Fluorescent Proteins | 2 | 2003 | 200 | 0.030 |
Why?
|
| Reproduction, Asexual | 1 | 2011 | 1 | 0.030 |
Why?
|
| Lipogenesis | 1 | 2011 | 9 | 0.030 |
Why?
|
| Dependovirus | 1 | 2012 | 34 | 0.030 |
Why?
|
| Genome, Mitochondrial | 1 | 2011 | 12 | 0.020 |
Why?
|
| Fungal Proteins | 1 | 2011 | 37 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2012 | 381 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2011 | 144 | 0.020 |
Why?
|
| Multigene Family | 1 | 2011 | 93 | 0.020 |
Why?
|
| Benzimidazoles | 1 | 2012 | 128 | 0.020 |
Why?
|
| DNA Primers | 2 | 2002 | 302 | 0.020 |
Why?
|
| Optical Imaging | 1 | 2012 | 46 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2012 | 258 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2011 | 188 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 2791 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2011 | 322 | 0.020 |
Why?
|
| Phylogeny | 1 | 2011 | 197 | 0.020 |
Why?
|
| Fatty Acids | 1 | 2011 | 222 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 1027 | 0.020 |
Why?
|
| Chemotaxis | 1 | 2010 | 38 | 0.020 |
Why?
|
| Fumonisins | 1 | 2010 | 14 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 2003 | 1447 | 0.020 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2010 | 29 | 0.020 |
Why?
|
| Serine C-Palmitoyltransferase | 1 | 2010 | 17 | 0.020 |
Why?
|
| Protein Phosphatase 2 | 1 | 2010 | 67 | 0.020 |
Why?
|
| Sphingomyelins | 1 | 2010 | 106 | 0.020 |
Why?
|
| NFATC Transcription Factors | 1 | 2009 | 40 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2010 | 160 | 0.020 |
Why?
|
| Endoplasmic Reticulum | 1 | 2010 | 148 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2010 | 215 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2008 | 140 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2009 | 202 | 0.020 |
Why?
|
| Tumor Protein p73 | 1 | 2007 | 4 | 0.020 |
Why?
|
| Integrases | 1 | 2008 | 31 | 0.020 |
Why?
|
| Drug Design | 1 | 2008 | 107 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 1174 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2007 | 176 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2007 | 120 | 0.020 |
Why?
|
| Larynx | 1 | 2007 | 49 | 0.020 |
Why?
|
| Cancer Vaccines | 1 | 2007 | 61 | 0.020 |
Why?
|
| Pharynx | 1 | 2007 | 89 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2007 | 274 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2007 | 284 | 0.020 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2007 | 132 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2010 | 1034 | 0.020 |
Why?
|
| Vaccination | 1 | 2007 | 189 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 2008 | 299 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2009 | 753 | 0.020 |
Why?
|
| Nanoparticles | 1 | 2008 | 254 | 0.020 |
Why?
|
| Clusterin | 1 | 2004 | 13 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2006 | 546 | 0.010 |
Why?
|
| Complement Inactivator Proteins | 1 | 2004 | 20 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2004 | 66 | 0.010 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2003 | 18 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2003 | 32 | 0.010 |
Why?
|
| Caspase 8 | 1 | 2003 | 40 | 0.010 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2003 | 19 | 0.010 |
Why?
|
| Astrocytoma | 1 | 2003 | 30 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2007 | 700 | 0.010 |
Why?
|
| Operator Regions, Genetic | 1 | 2003 | 5 | 0.010 |
Why?
|
| Molecular Chaperones | 1 | 2004 | 81 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2007 | 1553 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2007 | 902 | 0.010 |
Why?
|
| Glycoproteins | 1 | 2004 | 238 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 2002 | 85 | 0.010 |
Why?
|
| Repressor Proteins | 1 | 2003 | 183 | 0.010 |
Why?
|
| Middle Aged | 1 | 2020 | 21147 | 0.010 |
Why?
|
| Time Factors | 1 | 2010 | 4655 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2004 | 307 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2002 | 357 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2002 | 233 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2003 | 562 | 0.010 |
Why?
|